Showing results (321-330 of 757) with videos related to

Sort By:
Pageof 76
Innere Medizin (Heidelberg, Germany)|August 5, 2025
[InspeCKD: an analysis of the prevalence, diagnosis, and treatment of chronic kidney disease : Data from at-risk patients in German primary care]Christoph Wanner, Elke Schaeffner, Thomas Frese, et al.
International Journal of Cardiology|April 6, 2011
MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry diseaseSabrina Koeppe, Henning Neubauer, Frank Breunig, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 10, 2013
Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patientsChristiane Drechsler, Andreas Schneider, Lena Gutjahr-Lengsfeld, et al.
Clinical Chemistry|March 19, 2025
Carbamylated Albumin, Heart Failure, and Mortality in Patients Undergoing Coronary AngiographyBabak Yazdani, Graciela E Delgado, Anders H Berg, et al.
Circulation. Heart Failure|November 19, 2009
Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factorsGülmisal Güder, Stefan Frantz, Johann Bauersachs, et al.
Kidney International|December 22, 2016
Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies ConferenceRaphael Schiffmann, Derralynn A Hughes, Gabor E Linthorst, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 23, 2009
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysisVera Krane, Fritz Heinrich, Malte Meesmann, et al.
Circulation|January 21, 2009
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatmentFrank Weidemann, Markus Niemann, Frank Breunig, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 30, 2020
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational TrialAdeera Levin, Vlado Perkovic, David C Wheeler, et al.
Clinical Kidney Journal|September 26, 2022
Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitusFabian Hammer, Bernd Genser, Benjamin Dieplinger, et al.
Pageof 76